Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and Controls
NCT ID: NCT05812339
Last Updated: 2024-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
200 participants
OBSERVATIONAL
2022-11-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
GAS is intended to record, store, view and process gastric myoelectrical activity. This is a proprietary system consisting of multiple electrodes arranged on an array that is placed precisely over the stomach, a reader to collect the electrode measurements and a smart tablet application to track patient reported symptoms. Participants meeting inclusion and exclusion criteria will continue fasting for 30 minutes after the Gastric Alimetry System has been applied and begun measuring, eat a standard study meal within 10 minutes and remain quietly seated, reclining, for 4 hours as the GAS continues to collect data. The array is removed and the abdomen is examined for evidence of skin effects.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Motility Disorder Patients
Adults with history of confirmed motility disorder.
Gastric Alimetry System
Gastric Alimetry is a medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders. The device is indicated for use during the diagnostic work-up of patients reporting gastric symptoms, who are suspected of having an underlying gastric motility problem.
Healthy Controls
Adults meeting all inclusion and exclusion criteria with no symptoms or history of motility disorder.
Gastric Alimetry System
Gastric Alimetry is a medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders. The device is indicated for use during the diagnostic work-up of patients reporting gastric symptoms, who are suspected of having an underlying gastric motility problem.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gastric Alimetry System
Gastric Alimetry is a medical device intended to record, store, view and process gastric myoelectrical activity as an aid in the diagnosis of gastrointestinal motility disorders. The device is indicated for use during the diagnostic work-up of patients reporting gastric symptoms, who are suspected of having an underlying gastric motility problem.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adults aged 18 years and over
* Able to understand the risks/benefits of the study
* Able to give written informed consent
* No active gastrointestinal symptoms or pathology
* Resides in the Calgary, Alberta area
Patient Population:
* Adults aged 18 years and over
* BMI \> 35
* Able to understand the risks/benefits of the study
* Able to give written informed consent
* Patients meeting Rome IV Criteria for functional dyspepsia, or a nausea and vomiting disorder
* Patients with gastroparesis defined on a standardized gastric scintigraphy study
* Resides in the Calgary, Alberta area
Exclusion Criteria
* Under 18 years of age
* BMI \> 35
* Taking medications known to affect GI motility or the mid-gut axis (eg antidepressants, anti-anxiety medication, prokinetics, opiates)
* Metabolic, neurogenic, or endocrine disorders known to cause gastrointestinal dysmotility (eg. Multiple Sclerosis, Parkinson's disease, hypothyroidism)
* Known current GI infection (includes H. pylori when being actively treated)
* Known current inflammatory bowel disease
* Known current GI malignancy
* Known GI functional or motility disorders
* Previous gastroduodenal surgery
* GI functional or motility disorders
* Pregnant women
* Open abdominal wounds or abdominal skin not intact (eg rash, abrasions, weeping tissue)
* Fragile skin evidence by high susceptibility to skin tears or skin that bruises and breaks easily
* Allergy to adhesives
* History of allergy or intolerance to ingredients in the meal (nutrient drink, Ensure or similar and Clif bar or similar)
* No vulnerable groups such as; prisoners, individuals with known cognitive impairment, or institutionalised individuals be involved
* Regular cannabis use
* Diagnosed with, or suspected to have life-threatening conditions that could result in immediate danger
Patient Population:
* Under 18 years of age
* BMI \> 35
* Metabolic, neurogenic, or endocrine disorders known to cause gastrointestinal dysmotility (eg. Multiple Sclerosis, Parkinson's disease, hypothyroidism)
* Known current GI infection (includes H. pylori when being actively treated)
* Known current inflammatory bowel disease
* Known current GI malignancy
* Previous gastroduodenal surgery
* Open abdominal wounds or abdominal skin not intact (eg rash, abrasions, weeping tissue)
* Fragile skin evidence by high susceptibility to skin tears or skin that bruises and breaks easily
* Allergy to adhesives
* Pregnant women
* History of allergy or intolerance to ingredients in the meal (nutrient drink, Ensure or similar and Clif bar or similar)
* No vulnerable groups such as; prisoners, individuals with known cognitive impairment, or institutionalised individuals be involved
* Regular cannabis use except in the case of CHS
* Diagnosed with, or suspected to have life-threatening conditions that could result in immediate danger
* Inability to remain in a relaxed reclined position for the test duration
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Calgary
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christopher N Andrews, MD MSc FRCPC
Role: PRINCIPAL_INVESTIGATOR
University of Calgary
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Calgary
Calgary, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19-1925
Identifier Type: -
Identifier Source: org_study_id